Livzon Pharmaceutical Group Valuation
Is 1513 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1513 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1513 (HK$26.2) is trading below our estimate of fair value (HK$58.94)
Significantly Below Fair Value: 1513 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1513?
Key metric: As 1513 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 1513's PE Ratio? | |
|---|---|
| PE Ratio | 16.6x |
| Earnings | CN¥2.02b |
| Market Cap | CN¥29.87b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 7.3x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does 1513's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.2x | ||
3320 China Resources Pharmaceutical Group | 8x | 7.3% | HK$32.5b |
1177 Sino Biopharmaceutical | 26.1x | 12.9% | HK$60.1b |
867 China Medical System Holdings | 11.9x | 21.4% | HK$17.8b |
1093 CSPC Pharmaceutical Group | 10.7x | 2.7% | HK$59.3b |
1513 Livzon Pharmaceutical Group | 16.6x | 10.2% | HK$29.9b |
Price-To-Earnings vs Peers: 1513 is expensive based on its Price-To-Earnings Ratio (16.6x) compared to the peer average (14.2x).
Price to Earnings Ratio vs Industry
How does 1513's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 1513 is expensive based on its Price-To-Earnings Ratio (16.6x) compared to the Hong Kong Pharmaceuticals industry average (8x).
Price to Earnings Ratio vs Fair Ratio
What is 1513's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.6x |
| Fair PE Ratio | 12.4x |
Price-To-Earnings vs Fair Ratio: 1513 is expensive based on its Price-To-Earnings Ratio (16.6x) compared to the estimated Fair Price-To-Earnings Ratio (12.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
3SBio
HK$13.0b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.52
7D
-4.3%
1Y
-26.2%
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a